 Todd Bull
Concepts (338)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 45 | 2024 | 1981 | 3.730 |
Why?
| | Scleroderma, Systemic | 6 | 2019 | 125 | 1.610 |
Why?
| | Pulmonary Embolism | 5 | 2022 | 239 | 1.190 |
Why?
| | Ventricular Dysfunction, Right | 7 | 2023 | 247 | 1.170 |
Why?
| | Vena Cava Filters | 2 | 2020 | 64 | 0.760 |
Why?
| | Epoprostenol | 5 | 2024 | 132 | 0.720 |
Why?
| | Thrombolytic Therapy | 3 | 2021 | 157 | 0.710 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 77 | 0.650 |
Why?
| | Airway Obstruction | 1 | 2021 | 168 | 0.620 |
Why?
| | Antihypertensive Agents | 3 | 2024 | 518 | 0.600 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2024 | 1061 | 0.590 |
Why?
| | Familial Primary Pulmonary Hypertension | 12 | 2023 | 198 | 0.580 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 287 | 0.570 |
Why?
| | Oligonucleotide Array Sequence Analysis | 5 | 2010 | 763 | 0.550 |
Why?
| | Thrombosis | 4 | 2023 | 404 | 0.530 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2020 | 367 | 0.500 |
Why?
| | Growth Differentiation Factor 15 | 3 | 2013 | 42 | 0.500 |
Why?
| | Vascular Resistance | 5 | 2021 | 365 | 0.500 |
Why?
| | Exercise Test | 4 | 2024 | 623 | 0.480 |
Why?
| | Herpesviridae Infections | 3 | 2008 | 149 | 0.480 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 133 | 0.470 |
Why?
| | Hypoxia | 6 | 2024 | 1194 | 0.460 |
Why?
| | Endovascular Procedures | 1 | 2020 | 383 | 0.460 |
Why?
| | Altitude Sickness | 1 | 2017 | 151 | 0.450 |
Why?
| | Pulmonary Artery | 10 | 2023 | 1124 | 0.430 |
Why?
| | Vasodilator Agents | 4 | 2023 | 330 | 0.420 |
Why?
| | Echocardiography | 2 | 2020 | 653 | 0.410 |
Why?
| | Ventricular Function, Right | 5 | 2024 | 297 | 0.400 |
Why?
| | Humans | 70 | 2026 | 144748 | 0.400 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 933 | 0.380 |
Why?
| | Altitude | 1 | 2017 | 482 | 0.370 |
Why?
| | Anticoagulants | 5 | 2023 | 733 | 0.350 |
Why?
| | Sulfones | 1 | 2012 | 127 | 0.350 |
Why?
| | Endothelial Cells | 5 | 2011 | 849 | 0.350 |
Why?
| | Perioperative Care | 1 | 2014 | 235 | 0.350 |
Why?
| | Oxygen Consumption | 2 | 2024 | 724 | 0.330 |
Why?
| | Blood Cells | 1 | 2010 | 38 | 0.330 |
Why?
| | Walk Test | 3 | 2026 | 82 | 0.320 |
Why?
| | Herpesvirus 8, Human | 3 | 2008 | 67 | 0.310 |
Why?
| | Hypertension, Portal | 2 | 2020 | 65 | 0.310 |
Why?
| | Venous Thromboembolism | 3 | 2021 | 338 | 0.300 |
Why?
| | Piperazines | 1 | 2012 | 395 | 0.300 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 295 | 0.300 |
Why?
| | Blood Coagulation | 3 | 2021 | 273 | 0.300 |
Why?
| | End Stage Liver Disease | 2 | 2020 | 85 | 0.300 |
Why?
| | Virus Diseases | 1 | 2011 | 218 | 0.280 |
Why?
| | Exercise | 5 | 2026 | 2197 | 0.280 |
Why?
| | Lung | 8 | 2022 | 4131 | 0.260 |
Why?
| | Blood Vessels | 1 | 2008 | 175 | 0.250 |
Why?
| | Acute Lung Injury | 1 | 2010 | 307 | 0.250 |
Why?
| | Time Factors | 2 | 2017 | 7074 | 0.250 |
Why?
| | Middle Aged | 21 | 2026 | 35640 | 0.240 |
Why?
| | Heart Ventricles | 5 | 2024 | 756 | 0.240 |
Why?
| | Male | 29 | 2026 | 72211 | 0.230 |
Why?
| | Mixed Connective Tissue Disease | 1 | 2005 | 9 | 0.230 |
Why?
| | Microarray Analysis | 1 | 2005 | 118 | 0.230 |
Why?
| | Respiratory Function Tests | 1 | 2007 | 568 | 0.230 |
Why?
| | Muscle, Smooth, Vascular | 3 | 2007 | 450 | 0.230 |
Why?
| | Accelerometry | 1 | 2026 | 119 | 0.220 |
Why?
| | Cardiac Catheterization | 5 | 2023 | 552 | 0.220 |
Why?
| | Female | 28 | 2026 | 78074 | 0.220 |
Why?
| | Aromatase Inhibitors | 1 | 2024 | 58 | 0.210 |
Why?
| | Pulmonary Emphysema | 2 | 2007 | 311 | 0.210 |
Why?
| | Castleman Disease | 1 | 2003 | 15 | 0.200 |
Why?
| | Gene Expression Profiling | 2 | 2007 | 1801 | 0.180 |
Why?
| | Heparin | 2 | 2021 | 255 | 0.180 |
Why?
| | Biopsy | 1 | 2005 | 1091 | 0.180 |
Why?
| | Vascular Neoplasms | 1 | 2022 | 18 | 0.180 |
Why?
| | Cross-Over Studies | 1 | 2024 | 597 | 0.180 |
Why?
| | Endothelium, Vascular | 6 | 2007 | 965 | 0.170 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 25 | 0.170 |
Why?
| | Embolectomy | 1 | 2020 | 13 | 0.160 |
Why?
| | Aromatase | 1 | 2020 | 31 | 0.160 |
Why?
| | Growth Differentiation Factor 2 | 1 | 2020 | 2 | 0.160 |
Why?
| | Aged | 13 | 2026 | 25564 | 0.160 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 492 | 0.160 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2020 | 24 | 0.160 |
Why?
| | Pulmonary Circulation | 4 | 2023 | 429 | 0.160 |
Why?
| | Thrombectomy | 1 | 2020 | 79 | 0.150 |
Why?
| | Drug Resistance | 1 | 2020 | 153 | 0.150 |
Why?
| | Tuberculosis | 1 | 2003 | 288 | 0.150 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2020 | 142 | 0.150 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 241 | 0.150 |
Why?
| | Vascular Stiffness | 1 | 2023 | 466 | 0.140 |
Why?
| | Sildenafil Citrate | 2 | 2023 | 59 | 0.140 |
Why?
| | Risk Factors | 7 | 2018 | 10739 | 0.140 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1063 | 0.140 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2018 | 68 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 334 | 0.130 |
Why?
| | Estrogens | 1 | 2020 | 372 | 0.130 |
Why?
| | Acute Disease | 1 | 2020 | 1018 | 0.130 |
Why?
| | Thrombospondin 1 | 1 | 2017 | 28 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
| | Schistosoma | 1 | 2017 | 28 | 0.130 |
Why?
| | Critical Illness | 2 | 2021 | 875 | 0.130 |
Why?
| | Purines | 2 | 2023 | 185 | 0.130 |
Why?
| | Hemodynamics | 2 | 2014 | 1126 | 0.130 |
Why?
| | Natriuretic Peptide, Brain | 2 | 2021 | 107 | 0.120 |
Why?
| | Transforming Growth Factor beta | 2 | 2017 | 484 | 0.120 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2016 | 39 | 0.120 |
Why?
| | Risk Assessment | 3 | 2023 | 3595 | 0.120 |
Why?
| | Bone Marrow Cells | 1 | 2017 | 319 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1678 | 0.120 |
Why?
| | Systole | 1 | 2016 | 175 | 0.120 |
Why?
| | Adult | 15 | 2024 | 40359 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 381 | 0.110 |
Why?
| | Treatment Outcome | 8 | 2024 | 11498 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.110 |
Why?
| | Clinical Trials as Topic | 2 | 2013 | 1048 | 0.110 |
Why?
| | Cohort Studies | 3 | 2017 | 5895 | 0.110 |
Why?
| | Patient Care Team | 1 | 2020 | 687 | 0.110 |
Why?
| | Health Surveys | 1 | 2017 | 512 | 0.110 |
Why?
| | Myocardial Contraction | 1 | 2016 | 300 | 0.110 |
Why?
| | Prognosis | 3 | 2013 | 4207 | 0.110 |
Why?
| | Retrospective Studies | 8 | 2023 | 16942 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2011 | 92 | 0.110 |
Why?
| | Blood Pressure | 2 | 2016 | 1767 | 0.100 |
Why?
| | Intensive Care Units | 1 | 2020 | 896 | 0.100 |
Why?
| | Heart Failure | 2 | 2020 | 2147 | 0.100 |
Why?
| | ROC Curve | 1 | 2016 | 607 | 0.100 |
Why?
| | Heart-Assist Devices | 1 | 2020 | 573 | 0.100 |
Why?
| | Positive-Pressure Respiration | 1 | 2014 | 111 | 0.100 |
Why?
| | Anesthetics | 1 | 2014 | 98 | 0.100 |
Why?
| | Lung Diseases, Interstitial | 2 | 2013 | 664 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 447 | 0.100 |
Why?
| | Respiratory System Agents | 1 | 2013 | 23 | 0.100 |
Why?
| | Leukocytes, Mononuclear | 2 | 2007 | 580 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 150 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1566 | 0.090 |
Why?
| | Drug Storage | 1 | 2012 | 53 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2021 | 5345 | 0.090 |
Why?
| | Drug Stability | 1 | 2012 | 165 | 0.090 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2011 | 24 | 0.090 |
Why?
| | Drug Approval | 1 | 2012 | 88 | 0.090 |
Why?
| | Phenotype | 3 | 2010 | 3236 | 0.090 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2011 | 11 | 0.090 |
Why?
| | Troponin | 1 | 2011 | 46 | 0.090 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2011 | 38 | 0.090 |
Why?
| | Blood Gas Analysis | 1 | 2011 | 81 | 0.090 |
Why?
| | Europe | 1 | 2012 | 414 | 0.090 |
Why?
| | Hyponatremia | 1 | 2011 | 44 | 0.090 |
Why?
| | Reproducibility of Results | 2 | 2010 | 3403 | 0.090 |
Why?
| | Medical History Taking | 1 | 2011 | 118 | 0.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2011 | 84 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2020 | 3644 | 0.080 |
Why?
| | Antithrombins | 1 | 2011 | 70 | 0.080 |
Why?
| | Receptors, Interleukin-7 | 1 | 2010 | 27 | 0.080 |
Why?
| | Ultrasonography | 2 | 2011 | 774 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2024 | 2022 | 0.080 |
Why?
| | Quality of Life | 4 | 2026 | 3100 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3834 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2023 | 2098 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2011 | 347 | 0.080 |
Why?
| | Demography | 1 | 2010 | 297 | 0.080 |
Why?
| | Registries | 3 | 2022 | 2254 | 0.070 |
Why?
| | Aldosterone | 1 | 2009 | 43 | 0.070 |
Why?
| | Cluster Analysis | 1 | 2010 | 529 | 0.070 |
Why?
| | Vasopressins | 1 | 2009 | 60 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2012 | 378 | 0.070 |
Why?
| | Caspase 7 | 1 | 2008 | 22 | 0.070 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 138 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 994 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2022 | 2603 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2008 | 129 | 0.070 |
Why?
| | Bone Morphogenetic Protein 4 | 1 | 2008 | 43 | 0.070 |
Why?
| | Culture Media, Conditioned | 1 | 2008 | 111 | 0.070 |
Why?
| | Intramolecular Oxidoreductases | 2 | 2005 | 66 | 0.070 |
Why?
| | Electrocardiography | 1 | 2011 | 634 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 7956 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 383 | 0.070 |
Why?
| | Caspase 3 | 1 | 2008 | 252 | 0.070 |
Why?
| | Research Design | 1 | 2013 | 1126 | 0.070 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2005 | 161 | 0.060 |
Why?
| | Acrolein | 1 | 2007 | 22 | 0.060 |
Why?
| | Animals | 10 | 2017 | 38224 | 0.060 |
Why?
| | Survival Analysis | 1 | 2010 | 1333 | 0.060 |
Why?
| | United States | 4 | 2022 | 15694 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1514 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2010 | 1193 | 0.060 |
Why?
| | Colorado | 1 | 2017 | 4704 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2007 | 147 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 859 | 0.060 |
Why?
| | Endothelin A Receptor Antagonists | 1 | 2005 | 26 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 23 | 0.060 |
Why?
| | Endothelial Growth Factors | 2 | 2002 | 64 | 0.060 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2005 | 75 | 0.060 |
Why?
| | Comorbidity | 1 | 2010 | 1685 | 0.060 |
Why?
| | Lymphokines | 2 | 2002 | 131 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4185 | 0.050 |
Why?
| | Apoptosis | 3 | 2008 | 2514 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2008 | 752 | 0.050 |
Why?
| | Cattle | 2 | 2017 | 989 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2010 | 1132 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2008 | 792 | 0.050 |
Why?
| | CD36 Antigens | 1 | 2003 | 32 | 0.050 |
Why?
| | Vasodilation | 3 | 2010 | 518 | 0.050 |
Why?
| | Blood Circulation | 1 | 2003 | 44 | 0.050 |
Why?
| | E-Selectin | 1 | 2003 | 61 | 0.050 |
Why?
| | Forecasting | 1 | 2005 | 386 | 0.050 |
Why?
| | Nitriles | 1 | 2024 | 193 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1825 | 0.050 |
Why?
| | Veins | 1 | 2003 | 70 | 0.050 |
Why?
| | Blood | 1 | 2003 | 111 | 0.050 |
Why?
| | Biomarkers | 4 | 2013 | 4276 | 0.050 |
Why?
| | Blood Donors | 1 | 2004 | 118 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 689 | 0.050 |
Why?
| | Adolescent | 4 | 2021 | 22670 | 0.050 |
Why?
| | Hydralazine | 1 | 2022 | 6 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 597 | 0.050 |
Why?
| | Pulmonary Alveoli | 1 | 2005 | 393 | 0.050 |
Why?
| | Hydrazones | 1 | 2022 | 27 | 0.050 |
Why?
| | Postmenopause | 1 | 2024 | 379 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2005 | 1064 | 0.050 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 56 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2003 | 326 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2005 | 249 | 0.050 |
Why?
| | Drainage | 1 | 2003 | 185 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2016 | 4553 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2021 | 53 | 0.040 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 219 | 0.040 |
Why?
| | Cytochrome P-450 CYP1B1 | 1 | 2020 | 5 | 0.040 |
Why?
| | Vascular Remodeling | 1 | 2023 | 205 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1264 | 0.040 |
Why?
| | Catheters | 1 | 2021 | 75 | 0.040 |
Why?
| | Rivaroxaban | 1 | 2023 | 269 | 0.040 |
Why?
| | Brachial Artery | 2 | 1999 | 208 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2003 | 497 | 0.040 |
Why?
| | Liver Function Tests | 1 | 2020 | 107 | 0.040 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 72 | 0.040 |
Why?
| | Proteomics | 2 | 2022 | 1172 | 0.040 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2002 | 227 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5797 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 338 | 0.040 |
Why?
| | Outpatients | 1 | 2023 | 426 | 0.040 |
Why?
| | Smoking | 1 | 2007 | 1583 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1740 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2020 | 149 | 0.040 |
Why?
| | Mass Screening | 1 | 2007 | 1338 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2621 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 1296 | 0.040 |
Why?
| | Enalapril | 1 | 1998 | 16 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2022 | 294 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2026 | 3042 | 0.030 |
Why?
| | Hemorrhage | 1 | 2023 | 806 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2953 | 0.030 |
Why?
| | Antigens, Ly | 1 | 2017 | 41 | 0.030 |
Why?
| | Survival Rate | 1 | 2022 | 2025 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 370 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 102 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1998 | 199 | 0.030 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 2 | 2010 | 52 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2021 | 706 | 0.030 |
Why?
| | Education | 1 | 2017 | 107 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2020 | 399 | 0.030 |
Why?
| | Th2 Cells | 1 | 2017 | 180 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 892 | 0.030 |
Why?
| | Signal Transduction | 2 | 2020 | 5242 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2023 | 2551 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 545 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 502 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2016 | 882 | 0.030 |
Why?
| | Liver Transplantation | 1 | 2020 | 814 | 0.020 |
Why?
| | Hospitalization | 1 | 2023 | 2342 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2190 | 0.020 |
Why?
| | Perioperative Period | 1 | 2012 | 70 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 869 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2798 | 0.020 |
Why?
| | Mice | 2 | 2007 | 18497 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2011 | 25 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2011 | 53 | 0.020 |
Why?
| | International Cooperation | 1 | 2012 | 198 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 148 | 0.020 |
Why?
| | Vascular Endothelial Growth Factors | 2 | 2002 | 79 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 117 | 0.020 |
Why?
| | Nitric Oxide | 2 | 2010 | 900 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2011 | 243 | 0.020 |
Why?
| | Introns | 1 | 2011 | 255 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8103 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2905 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2011 | 180 | 0.020 |
Why?
| | Physical Examination | 1 | 2012 | 246 | 0.020 |
Why?
| | RNA Splicing | 1 | 2011 | 278 | 0.020 |
Why?
| | Radiation Dosage | 1 | 2011 | 194 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2011 | 261 | 0.020 |
Why?
| | Leg | 1 | 2011 | 241 | 0.020 |
Why?
| | Lung Transplantation | 1 | 2013 | 325 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2017 | 2856 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2002 | 562 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 36 | 0.020 |
Why?
| | Anesthesia | 1 | 2012 | 251 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 626 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 58 | 0.020 |
Why?
| | Contrast Media | 1 | 2011 | 484 | 0.020 |
Why?
| | Binding Sites | 1 | 2011 | 1330 | 0.020 |
Why?
| | Health Status Indicators | 1 | 2009 | 161 | 0.020 |
Why?
| | Endothelin-1 | 1 | 2010 | 177 | 0.020 |
Why?
| | Mutation | 3 | 2005 | 4080 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 6054 | 0.010 |
Why?
| | Research | 1 | 2009 | 439 | 0.010 |
Why?
| | Protein Binding | 1 | 2011 | 2277 | 0.010 |
Why?
| | Gene Expression | 1 | 2010 | 1505 | 0.010 |
Why?
| | Young Adult | 1 | 2021 | 14021 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 323 | 0.010 |
Why?
| | Cell Culture Techniques | 1 | 2007 | 376 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2011 | 1526 | 0.010 |
Why?
| | Genes, Viral | 1 | 2003 | 93 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1762 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1848 | 0.010 |
Why?
| | Cyclins | 1 | 2003 | 101 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 108 | 0.010 |
Why?
| | Disease Progression | 1 | 2010 | 2889 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2007 | 2188 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2005 | 419 | 0.010 |
Why?
| | DNA, Viral | 1 | 2003 | 367 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 1998 | 3862 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 2001 | 161 | 0.010 |
Why?
| | Viral Proteins | 1 | 2003 | 370 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2003 | 825 | 0.010 |
Why?
| | Vasoconstriction | 1 | 2001 | 216 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2012 | 2938 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2001 | 404 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 6062 | 0.010 |
Why?
| | Ultrasonography, Doppler, Pulsed | 1 | 1999 | 7 | 0.010 |
Why?
| | Administration, Sublingual | 1 | 1999 | 12 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 591 | 0.010 |
Why?
| | Nitroglycerin | 1 | 1999 | 14 | 0.010 |
Why?
| | Pregnancy | 1 | 2011 | 7211 | 0.010 |
Why?
| | Lipoprotein(a) | 1 | 1999 | 68 | 0.010 |
Why?
| | Cholesterol, HDL | 1 | 1999 | 197 | 0.010 |
Why?
| | Arteriosclerosis | 1 | 1998 | 83 | 0.010 |
Why?
| | Fibrinogen | 1 | 1999 | 180 | 0.010 |
Why?
| | Video Recording | 1 | 1999 | 210 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 415 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 814 | 0.010 |
Why?
| | Diabetic Angiopathies | 1 | 1998 | 252 | 0.010 |
Why?
| | Regression Analysis | 1 | 1998 | 1014 | 0.010 |
Why?
| | Military Personnel | 1 | 1999 | 692 | 0.010 |
Why?
|
|
Bull's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|